Results 41 to 50 of about 7,402 (202)

Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics. [PDF]

HIV Med
Abstract Objectives Long‐acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real‐world data in East Asia remain scarce. This study aims to evaluate the impact of CAB+RPV in people with HIV in Japan, focusing on virological outcomes, treatment continuation and inflammatory markers, providing valuable insight ...
Adachi E, Minami R, Shirano M, Nakamura H, Fukushima K, Imahashi M, Sekiya R, Yoshino Y, Taniguchi T, J‐HIV RWD Collaborative Database Team.   +9 more
europepmc   +2 more sources

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies. [PDF]

, 2017
BACKGROUND: Antiretroviral therapy in human immunodeficiency virus (HIV)-infected women and blacks merits particular scrutiny because these groups have been underrepresented in clinical trials.
Bekker, Linda-Gail, DiNubile, Mark J, Katlama, Christine, Leavitt, Randi Y, Rodgers, Anthony J, Sklar, Peter A, Squires, Kathleen E., Teppler, Hedy, Yazdanpanah, Yazdan, Zhou, Yan   +9 more
core   +2 more sources

Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis - a case report

BMC Nephrology, 2020
Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD).
José Ramón Santos, Ana Merino, Walter E. Haefeli, Cristina Miranda, Marisol Prats, Ioana Bancu, Lucía Bailón, José Moltó   +7 more
doaj   +1 more source

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are ...
Sandra De Meyer, Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme, Christophe Buyck, Marnix Van Loock, Brian Woodfall, Sandra Ciesek   +7 more
doaj   +1 more source

Risk factors contributing to a low darunavir plasma concentration [PDF]

, 2017
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
Alffenaar, Jan Willem C., Bierman, Wouter F.W., Daskapan, Alper, Kosterink, Jos G.W., Stienstra, Ymkje, Touw, Daan J., van der Werf, Tjip S.   +6 more
core   +2 more sources

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Pharmaceutics, 2023
Background: The clinical outcomes of antiretroviral drugs may be modified through drug interactions; thus, it is important to update the drug interactions in people living with HIV (PLHIV). Aim: To update clinically relevant drug interactions in PLHIV on
Pedro Amariles, Mónica Rivera-Cadavid, Mauricio Ceballos   +2 more
doaj   +1 more source

Aspectos farmacológicos de darunavir/cobicistat

Enfermedades Infecciosas y Microbiología Clínica, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad bien conocido.
González-Doménech, Carmen María, Palacios-Muñoz, María Rosario, Santos-González, Jesús Leandro   +2 more
openaire   +3 more sources

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection [PDF]

, 2014
A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir ...
Abbas, R., Baer, R., Boyd, M., Gracey, D., Holt, S., Irish, A., Levy, M., Mudge, D., Sevastos, J., Walker, R.   +9 more
core   +3 more sources

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Drugs in Context, 2019
The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to ...
Melissa E Badowski, Bradley Burton, Kristy M Shaeer, John Dicristofano   +3 more
doaj   +1 more source

Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes. [PDF]

, 2017
BackgroundThe Literature on rhabdomyolysis in the HIV-positive population is sparse and limited. We aimed to explore the incidence, patient characteristics, etiologies and outcomes of rhabdomyolysis in a cohort of HIV-positive patients identified through
Atta, Mohamed G, Estrella, Michelle M, Fine, Derek M, Koubar, Sahar H, Lucas, Gregory M, Moore, Richard D, Warrier, Rugmini   +6 more
core   +1 more source